CJC-1295 vs Ipamorelin: A Research Comparison

Search interest in CJC-1295 and Ipamorelin almost always arrives as a pair, because the two peptides are routinely discussed together as complementary tools for stimulating the body’s own release of growth hormone (GH). They are, however, chemically and pharmacologically distinct molecules that engage different receptors, were created by different companies, and were originally developed for different indications. This comparison sets out what the primary literature actually establishes about each, rather than how they are marketed.

Researchers who look up this pairing are usually trying to understand how a growth-hormone-releasing hormone (GHRH) analog differs from a ghrelin-receptor agonist, why the two sit on very different pharmacokinetic timelines, and where each stands in terms of published evidence and regulatory status. Both remain research compounds: neither is an approved therapeutic for growth-hormone stimulation in humans.

Research-only notice: CJC-1295 and ipamorelin are investigational compounds intended for laboratory and research use. Neither is approved by the FDA or comparable regulators for human therapeutic use. Nothing on this page is medical advice, a dosing recommendation, or an endorsement of use in humans.

Mechanism: two different doors to the same room

The clearest distinction between these peptides is the receptor each one targets. CJC-1295 is an analog of the first 29 amino acids of GHRH, the hypothalamic hormone that normally instructs the pituitary to make and release GH. It binds the pituitary GHRH receptor and amplifies that natural signal. The molecule’s defining trick is its Drug Affinity Complex (DAC): a maleimido-propionic acid linker that reacts covalently with cysteine-34 on circulating serum albumin, tethering the peptide to a large, slowly cleared carrier protein. In the early human study by Teichman and colleagues, this extended the estimated half-life to roughly 5.8-8.1 days and produced dose-dependent rises in mean plasma GH (2- to 10-fold) and IGF-1 (1.5- to 3-fold) lasting many days after a single injection. A separate, shorter form without the linker, often labeled “modified GRF(1-29)” or CJC-1295 no-DAC, keeps the GHRH-receptor mechanism but has a half-life closer to 30 minutes.

Ipamorelin works through a completely separate pathway. It is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as an agonist at the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the hormone ghrelin. Rather than mimicking GHRH, it mimics ghrelin, promoting GH release and reducing the inhibitory tone of somatostatin. In the foundational characterization by Raun and colleagues at Novo Nordisk, ipamorelin released GH with potency comparable to the earlier peptide GHRP-6, but with a critical difference: it did not meaningfully raise ACTH or cortisol even at doses more than 200-fold above its GH-releasing ED50. That selectivity, described as the first GHRP-receptor agonist with GH selectivity resembling GHRH itself, is the property most often cited as ipamorelin’s distinguishing feature relative to older secretagogues such as GHRP-2 and GHRP-6.

Because the two peptides act on different receptors that both feed into GH release, they are frequently studied as a mechanistically complementary pair in preclinical settings. This is a statement about their pharmacology, not a usage recommendation.

Evidence and development status

Neither compound has completed the pivotal efficacy trials needed for approval, but their paper trails differ in character. CJC-1295’s most-cited human data come from the Teichman pharmacokinetic and pharmacodynamic study in healthy adults, which established its long duration of action and general short-term tolerability. Its clinical development, run by ConjuChem for HIV-associated lipodystrophy and visceral obesity, was halted at Phase 2 after a participant death that the attending physician attributed to pre-existing coronary disease rather than the drug; development was discontinued as a precaution. As a result, there are no completed late-stage efficacy trials for CJC-1295.

Ipamorelin has a broader preclinical footprint and reached human trials for a non-GH indication. Novo Nordisk (and later Helsinn) advanced it primarily for gastrointestinal motility disorders, reasoning that a ghrelin mimetic might accelerate recovery of gut function. A multicenter, double-blind, placebo-controlled Phase 2 proof-of-concept study by Beck and colleagues tested intravenous ipamorelin for postoperative ileus after bowel resection and found no significant differences from placebo on its key efficacy endpoints. The program was subsequently discontinued. In short, ipamorelin has more human clinical exposure, but that exposure produced a negative result in its main tested indication, and its growth-hormone applications remain preclinical and off-label.

Research context

The framing that emerges from the literature is one of pace and pattern. CJC-1295 with DAC is long-acting, producing a broad, sustained elevation in GH and IGF-1 that does not closely track the body’s normal pulsatile rhythm; its multi-day half-life means effects persist well beyond a single administration. Ipamorelin is short-acting, with a roughly two-hour half-life, and tends toward a more discrete, pulse-like GH response consistent with its ghrelin-receptor mechanism. Its documented selectivity (minimal cortisol and ACTH effect) is a recurring reason it is studied where off-target endocrine activity is a concern.

Key differences

• Receptor target: CJC-1295 activates the GHRH receptor; ipamorelin activates the ghrelin/GHS-R1a receptor.
• Duration: The DAC form of CJC-1295 lasts on the order of days; ipamorelin lasts on the order of hours.
• GH pattern: CJC-1295 favors sustained GH/IGF-1 elevation; ipamorelin favors a shorter, more pulse-like release.
• Selectivity: Ipamorelin is documented as not meaningfully raising ACTH or cortisol; CJC-1295 acts upstream through the native GHRH pathway.
• Clinical trial record: CJC-1295’s key human data are early-phase pharmacokinetics; ipamorelin reached a Phase 2 GI trial that missed its endpoints.

Which for what research?

Framed strictly as research questions, the two peptides map onto different experimental goals. A protocol probing prolonged, tonic elevation of GH and IGF-1, or modeling long-acting GHRH-receptor stimulation, is the context where CJC-1295 (particularly the DAC form) appears in the literature. A protocol focused on acute, pulse-like GH release with minimal disturbance of the adrenal axis, or on ghrelin-receptor pharmacology and gut motility, is the context where ipamorelin appears. None of this is guidance for human use; both compounds are unapproved and their safety profiles in humans are incompletely defined. Put these side by side in the Compare Peptides tool.

Sources

• Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed 16352683
• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed 9849822
• Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. PubMed 25331030